论文信息 - Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial - 字舞流文

Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial

U. Schmidt-Erfurth | S. Sivaprasad | E. Souied | G. Virgili | F. Boscia | A. Grzybowski | M. McKibbin | K. Emmerich | S. Teper | W. Sekundo | A. Lotery | L. Kodjikian | M. Rękas | F. Bandello | J. Garweg | M. Alexík | E. Midena | A. Adán | Manuel Falcão | E. Peiretti | B. Romanowska-Dixon | I. Petropoulos | N. Feltgen | M. Nicolò | C. Eandi | V. Balciuniene | F. Viola | J. Figueira | S. Leal | Attila Vajas | A. Seres | Z. Michalewska | A. Wedrich | F. Ricci | Gabriela Pavlovičová | T. Schmelter | A. Papp | E. Cervera | J. Štefanickova | C. Dahlke | S. Vaz-Pereira | E. Graczynska | Jesia Hasan | T. Żarnowski | J. Kałużny | L. Sararols | D. Sandner | B. Varsányi | T. Niesen | J. Dusová | K. Struhařová | A. Burés | J. Hamouz | C. Hoyng | F. Holz | D. Varma | David Chow | M. Giunta | Á. Kerényi | D. Raczyńska | M. Amaro | J. Sousa | Ursula Andreas Fareed David John Michel Jesia Jaroslava J Schmidt-Erfurth Wedrich Ali Chow Dickinson | F. Ali | J. Dickinson | F. Koch | A. Cimbalas | M. Gajdosova | Lluis Arias Barquet | Carlos Cava Valenciano | A. Vajas | M. Mckibbin

[1] Jennifer K. Sun,et al. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). , 2020, Ophthalmology.

[2] S. Sivaprasad,et al. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study. , 2019, Ophthalmology. Retina.

[3] N. Bressler,et al. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial , 2018, JAMA ophthalmology.

[4] A. Loewenstein,et al. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases , 2017, Graefe's Archive for Clinical and Experimental Ophthalmology.

[5] Bianca S. Gerendas,et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA) , 2017, Ophthalmologica.

[6] A. Ringwald,et al. Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials , 2017, BMC Ophthalmology.

[7] P. Kaiser,et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. , 2016, Ophthalmology.

[8] N. Bressler,et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. , 2016, Ophthalmology.

[9] P. Kaiser,et al. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. , 2015, Ophthalmology.

[10] T. Wong,et al. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss , 2015, Eye and Vision.

[11] Carsten Framme,et al. TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations , 2015, Retina.

[12] S. Sanjay,et al. Updates in the Management of Diabetic Macular Edema , 2015, Journal of diabetes research.

[13] N. Bressler,et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. , 2015, Ophthalmology.

[14] P. Kaiser,et al. Intravitreal aflibercept for diabetic macular edema. , 2014, Ophthalmology.

[15] Judy E. Kim,et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. , 2012, Archives of ophthalmology.

[16] P. Vécsei-Marlovits,et al. TIME TO FIRST TREATMENT: The Significance of Early Treatment of Exudative Age-related Macular Degeneration , 2012, Retina.

[17] Lloyd Paul Aiello,et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema , 2010, Ophthalmology.

[18] G. Yılmaz,et al. Clinical Interventions in Aging Dovepress Visual Outcome of Intravitreal Ranibizumab for Exudative Age-related Macular Degeneration: Timing and Prognosis Çag ˘la Sarıtürk , 2022 .